GleamWall
中文EN

HRMY Harmony Biosciences Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%

Margins

Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—

Returns

ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$268.92M$261.28M$215.39M$243.78M$239.46M$200.49M$184.73M$201.27M
Cost of revenue$80.69M$63.20M$44.51M$68.55M$59.65M$38.15M$31.99M$54.41M
Gross profit$188.23M$198.08M$170.88M$175.23M$179.81M$162.34M$152.74M$146.86M
R&D expense$71.66M$46.60M$69.38M$49.93M$54.96M$50.16M$34.54M$34.67M
SG&A expense$27.65M$28.05M$32.51M$57.56M$29.81M$33.92M$31.24M$28.86M
Operating income$54.20M$89.32M$37.29M$38.56M$65.49M$48.18M$56.24M$55.73M
Interest expense$3.06M$3.07M$3.23M$3.55M$3.62M$3.65M$3.84M$4.21M
Pretax income$59.25M$93.27M$39.69M$40.76M$67.49M$49.64M$57.18M$56.16M
Income tax$11.05M$17.83M$7.20M$18.27M$16.62M$9.86M$11.62M$6.68M
Net income$48.20M$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M
EBITDA$54.20M$89.32M$37.30M—$65.49M$48.19M$56.25M$55.73M
EPS (basic)0.831.300.56—0.880.690.79—
EPS (diluted)0.811.280.55—0.870.680.78—
Weighted avg. shares (diluted)59.68M58.76M58.78M—58.72M58.43M58.52M—
Balance sheet
Cash & equivalents$647.10M$549.77M$589.40M$752.50M$647.27M$546.32M$489.27M$453.27M
Short-term investments$124.04M$118.02M$51.52M$22.84M$25.58M$19.22M$17.95M$14.19M
Receivables$127.74M$111.00M$108.22M$96.79M$100.65M$92.98M$105.97M$83.03M
Inventory$5.87M$6.36M$5.28M$5.36M$6.88M$6.10M$6.38M$7.20M
Current assets$934.83M$814.33M$778.82M$907.01M$838.80M$691.35M$642.69M$579.25M
PP&E, net————$1.44M$1.38M$1.38M$1.26M
Intangibles$71.53M$77.50M$83.46M$89.42M$95.38M$101.34M$107.30M$113.26M
Total assets$1.48B$1.37B$1.27B$1.27B$1.21B$1.11B$1.06B$999.20M
Current liabilities$271.54M$234.07M$217.34M$252.13M$223.40M$180.13M$175.12M$175.08M
Short-term debt$20.00M$20.00M$20.00M$20.00M$20.00M$18.75M$17.50M$16.25M
Long-term debt$129.10M$133.96M$138.81M$143.66M$148.51M$153.34M$158.18M$163.02M
Total debt$149.10M$153.96M$158.81M$163.66M$168.51M$172.09M$175.68M$179.27M
Total liabilities$406.01M$373.84M$361.48M$401.41M$373.10M$334.93M$335.01M$340.05M
Shareholders' equity$1.07B$999.24M$910.35M$870.22M$835.12M$773.08M$720.52M$659.15M
Net debt-$498.00M-$395.81M-$430.58M-$588.84M-$478.76M-$374.23M-$313.59M-$274.00M
Shares outstanding58.72M58.12M57.87M57.73M57.60M57.54M57.39M57.14M
Cash flow statement
Operating cash flow$76.69M$92.43M$27.76M$126.15M$108.73M$79.33M$33.99M$75.56M
Capital expenditure———$107,000$71,000$4,000$128,000$513,000
Free cash flow———$126.04M$108.66M$79.32M$33.86M$75.05M
Investing cash flow$7.68M-$131.50M-$183.65M-$17.63M-$4.79M-$19.59M$2.36M-$7.19M
Financing cash flow$12.96M-$558,000-$7.22M-$3.02M-$3.00M-$2.69M-$352,000-$2.74M
Depreciation & amortization$7,000$7,000$7,000—$7,000$6,000$7,000$6,000
Stock-based compensation$8.13M$9.58M$10.62M$9.97M$10.82M$11.39M$12.50M$10.07M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.